Summary

Europe postpartum hemorrhage treatment devices market is expected to reach USD 397.15 million by 2032 from USD 274.95 million in 2024, growing at a CAGR of 4.7% in the forecast period of 2025 to 2032.
Market Segmentation:
Europe Postpartum Hemorrhage Treatment Devices Market, By Type (Uterine Balloon Tamponade, Uniject Prefilled Injection System, Non-Pneumatic Anti-Shock Garment, Vacuum-Induced Hemorrhage Control Devices, and Others), Condition (Major Postpartum Hemorrhage (More Than 1000 ML), Minor Postpartum Hemorrhage (500-1000 ML), and Massive Postpartum Hemorrhage (2000 ML or More), and Secondary Postpartum Hemorrhage), Patient Type (Primary PPH and Secondary PPH), End User (Hospitals, Maternity Centers, Specialty Clinics, Home Care Settings, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Germany, France, U.K., Italy , Spain , Russia ,Turkey, Netherland, Poland, Belgium, Switzerland, Sweden, Denmark, Norway, Finland, and Rest of Europe) - Industry Trends & Forecast To 2032


Overview of Europe Postpartum Hemorrhage Treatment Market Dynamics:

Driver

• Rising incidence of postpartum hemorrhage

Restraint

• Side effects associated with the postpartum hemorrhage treatment
Opportunity

• Training and educational programs for proper use of PPH treatment devices

• Market Players:

The key market players operating in the Europe postpartum hemorrhage treatment market are listed below:

• Coagulant Therapeutics
• Biomedical
• BD
• Organon group of companies
• Laborie
• CooperCompanies
• Belmont Medical Technologies
• PRIVATE LIMITED
• Krishco Medical Products Pvt. Ltd.
• 3rd Stone Design
• Advin Health Care

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF THE EUROPE POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET 34
1.4 LIMITATIONS 35
1.5 MARKETS COVERED 35
2 MARKET SEGMENTATION 38
2.1 MARKETS COVERED 38
2.2 GEOGRAPHICAL SCOPE 39
2.3 YEARS CONSIDERED FOR THE STUDY 40
2.4 CURRENCY AND PRICING 40
2.5 DBMR TRIPOD DATA VALIDATION MODEL 41
2.6 MULTIVARIATE MODELLING 44
2.7 TYPE LIFELINE CURVE 45
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 46
2.9 DBMR MARKET POSITION GRID 47
2.10 VENDOR SHARE ANALYSIS 48
2.11 MARKET END USER COVERAGE GRID 49
2.12 SECONDARY SOURCES 50
2.13 ASSUMPTIONS 50
3 EXECUTIVE SUMMARY 51
4 PREMIUM INSIGHTS 55
4.1 PESTAL ANALYSIS 57
4.2 PORTERS FIVE FORCES ANALYSIS 58
4.3 INDUSTRY INSIGHTS 59
4.3.1 MICRO AND MACROECONOMIC FACTORS 59
4.3.2 PENETRATION AND GROWTH PROSPECT MAPPING 59
4.3.3 KEY PRICING STRATEGIES 59
4.4 COST ANALYSIS BREAKDOWN 60
4.5 TECHNOLOGY ROADMAP 60
4.6 VALUE CHAIN ANALYSIS 61
4.7 OPPORTUNITY MAP ANALYSIS 61
4.8 HEALTHCARE ECONOMY 61
4.9 REIMBURSEMENT FRAMEWORK 62
4.10 TARIFFS AND ITS IMPACT ON THE MARKET 63
4.10.1 DEFINITION AND IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR 63
4.10.2 EUROPE VS. REGIONAL TARIFF STRUCTURES 63
4.10.3 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY 63
4.10.4 TARIFF REGULATIONS IN KEY MARKETS 64
4.10.4.1 MEDICARE/MEDICAID TARIFF POLICIES 64
4.10.4.2 CMS PRICING MODELS 64
4.10.4.3 OTHERS 64
4.10.5 TARIFFS ON MEDICAL DEVICES & EQUIPMENT 64
4.10.5.1 IMPORT/EXPORT DUTIES ON MEDICAL EQUIPMENT 64
4.10.5.2 IMPACT ON PRICING AND AVAILABILITY OF HIGH-END MEDICAL TECHNOLOGY 64
4.10.5.3 CASE STUDIES OF TARIFF CHANGES AFFECTING THE INDUSTRY 65
4.10.6 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES 65
4.10.7 TARIFF EXEMPTIONS AND INCENTIVES 65
4.10.8 DUTY-FREE IMPORTS FOR ESSENTIAL MEDICINES AND VACCINES 65
4.10.9 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN 66
4.10.10 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS 66
5 REGULATORY FRAMEWORK 67
6 MARKET OVERVIEW 70
6.1 DRIVERS 72
6.1.1 RISING INCIDENCE OF POSTPARTUM HAEMORRHAGE 72
6.1.2 ONGOING TECHNOLOGICAL ADVANCEMENTS FOR POSTPARTUM HEMORRHAGE TREATMENTS 73
6.1.3 RISING BIRTH RATES ASSOCIATED WITH AN INCREASE IN THE NUMBER OF POSTPARTUM HEMORRHAGE 74
6.1.4 REGULATORY SUPPORT AND APPROVALS ASSOCIATED WITH THE TREATMENT DEVICES 75
6.2 RESTRAINTS 76
6.2.1 SIDE EFFECTS ASSOCIATED WITH THE POSTPARTUM HEMORRHAGE TREATMENT 76
6.2.2 LIMITED RESEARCH AND DEVELOPMENT FOR PPH TREATMENT 77
6.3 OPPORTUNITIES 78
6.3.1 TRAINING AND EDUCATIONAL PROGRAMS FOR PROPER USE OF PPH TREATMENT DEVICES 78
6.3.2 SUPPORT FROM GOVERNMENTAL AND NON-GOVERNMENTAL ORGANIZATIONS IN PPH DEVICE ADOPTION 79
6.3.3 TELEMEDICINE INTEGRATION TO ENHANCE POSTPARTUM HEMORRHAGE DEVICE USE 80
6.4 CHALLENGES 81
6.4.1 ENVIRONMENTAL IMPACT AND DISPOSAL ISSUES OF SINGLE-USE PPH DEVICES 81
6.4.2 STERILITY CHALLENGES AND INFECTION RISKS IN PPH DEVICES 82
7 EUROPE POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY TYPE 83
7.1 OVERVIEW 84
7.2 UTERINE BALLOON TAMPONADE 87
7.2.1 BAKRI BALLOON 88
7.2.1.1 BAKRI POSTPARTUM BALLOON 88
7.2.1.2 BAKRI POSTPARTUM BALLOON WITH RAPID INSTILLATION COMPONENTS 88
7.2.2 FOLEY CATHETER 89
7.2.2.1 STANDARD FOLEY CATHETER 89
7.2.2.2 CONDOM-LOADED FOLEY CATHETER 89
7.3 UNIJECT PREFILLED INJECTION SYSTEM 90
7.3.1 OXYTOCIN-BASED INJECTION SYSTEM 90
7.3.2 CARBETOCIN-BASED INJECTION SYSTEM 90
7.4 NON-PNEUMATIC ANTI-SHOCK GARMENT 91
7.4.1 STANDARD NON-PNEUMATIC ANTI-SHOCK GARMENT 92
7.4.1.1 MEDIUM 92
7.4.1.2 LARGE 92
7.4.2 MODIFIED NON-PNEUMATIC ANTI-SHOCK GARMENT 92
7.4.2.1 MEDIUM 92
7.4.2.2 LARGE 92
7.5 VACUUM-INDUCED HEMORRHAGE CONTROL DEVICES 93
7.5.1 JADA SYSTEM 93
7.5.2 OTHERS 93
7.6 OTHERS 94
7.6.1 COMPRESSION DEVICES 95
7.6.1.1 B-LYNCH 95
7.6.1.2 HAYMAN 95
7.6.1.3 OTHER 95
7.6.2 UTERINE ARTERY LIGATION PRODUCTS 95
7.6.3 OTHERS 95
8 EUROPE POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY PATIENT TYPE 96
8.1 OVERVIEW 97
8.2 PRIMARY PPH 100
8.3 SECONDARY PPH 101
9 EUROPE POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY CONDITION 102
9.1 OVERVIEW 103
9.2 MAJOR POSTPARTUM HEMORRHAGE (MORE THAN 1000 ML) 106
9.3 MINOR POSTPARTUM HEMORRHAGE (500-1000 ML) 107
9.4 MASSIVE POSTPARTUM HEMORRHAGE (2000 ML OR MORE) 108
9.5 SECONDARY POSTPARTUM HEMORRHAGE 108
10 EUROPE POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY DISTRIBUTION CHANNEL 109
10.1 OVERVIEW 110
10.2 DIRECT TENDER 113
10.3 RETAIL SALES 114
10.3.1 OFFLINE SALES 114
10.3.2 ONLINE SALES 114
10.4 OTHERS 115
11 EUROPE POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY END USER 116
11.1 OVERVIEW 117
11.2 HOSPITALS 120
11.2.1 PUBLIC HOSPITALS 121
11.2.1.1 TIER 2 121
11.2.1.2 TIER 3 121
11.2.1.3 TIER 1 121
11.2.2 PRIVATE HOSPITALS 122
11.2.2.1 TIER 2 122
11.2.2.2 TIER 3 122
11.2.2.3 TIER 1 122
11.3 MATERNITY CENTERS 123
11.4 SPECIALTY CLINICS 124
11.5 HOME CARE SETTINGS 124
11.6 OTHERS 125
12 EUROPE POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET, BY REGION 126
12.1 EUROPE 128
12.1.1 GERMANY 135
12.1.2 FRANCE 141
12.1.3 U.K. 147
12.1.4 ITALY 153
12.1.5 SPAIN 159
12.1.6 RUSSIA 165
12.1.7 TURKEY 171
12.1.8 NETHERLAND 177
12.1.9 POLAND 183
12.1.10 BELGIUM 189
12.1.11 SWITZERLAND 195
12.1.12 SWEDEN 201
12.1.13 DENMARK 207
12.1.14 NORWAY 213
12.1.15 FINLAND 219
12.1.16 REST OF EUROPE 225
13 EUROPE POSTPARTUM HEMORRHAGE TREATMENT DEVICES MARKET: COMPANY LANDSCAPE 226
13.1 COMPANY SHARE ANALYSIS: GLOBAL 226
14 SWOT ANALYSIS 227
15 COMPANY PROFILES 228
15.1 BD 228
15.1.1 COMPANY SNAPSHOT 228
15.1.2 REVENUE ANALYSIS 229
15.1.3 COMPANY SHARE ANALYSIS 229
15.1.4 SOLUTION PORTFOLIO 230
15.1.5 RECENT NEWS 230
15.2 ORGANON GROUP OF COMPANIES 231
15.2.1 COMPANY SNAPSHOT 231
15.2.2 REVENUE ANALYSIS 231
15.2.3 COMPANY SHARE ANALYSIS 232
15.2.4 PRODUCT PORTFOLIO 232
15.2.5 RECENT DEVELOPMENTS/NEWS 233
15.3 LABORIE 234
15.3.1 COMPANY SNAPSHOT 234
15.3.2 COMPANY SHARE ANALYSIS 234
15.3.3 PRODUCT PORTFOLIO 235
15.3.4 RECENT DEVELOPMENT 235
15.4 COOPERCOMPANIES 236
15.4.1 COMPANY SNAPSHOT 236
15.4.2 REVENUE ANALYSIS 236
15.4.3 COMPANY SHARE ANALYSIS 237
15.4.4 PRODUCT PORTFOLIO 237
15.4.5 RECENT DEVELOPMENT 237
15.5 BELMONT MEDICAL TECHNOLOGIES 238
15.5.1 COMPANY SNAPSHOT 238
15.5.2 COMPANY SHARE ANALYSIS 238
15.5.3 PRODUCT PORTFOLIO 239
15.5.4 RECENT DEVELOPMENT 239
15.6 ADVIN HEALTH CARE 240
15.6.1 COMPANY SNAPSHOT 240
15.6.2 PRODUCT PORTFOLIO 240
15.6.3 RECENT DEVELOPMENTS 240
15.7 ANGIPLAST PRIVATE LIMITED 241
15.7.1 COMPANY SNAPSHOT 241
15.7.2 PRODUCT PORTFOLIO 241
15.7.3 RECENT DEVELOPMENT 241
15.8 COAGULANT THERAPEUTICS 242
15.8.1 COMPANY SNAPSHOT 242
15.8.2 PIPELINE PORTFOLIO 242
15.8.3 RECENT DEVELOPMENT 242
15.9 KRISHCO MEDICAL PRODUCTS PVT. LTD 243
15.9.1 COMPANY SNAPSHOT 243
15.9.2 PRODUCT PORTFOLIO 243
15.9.3 RECENT DEVELOPMENT 244
15.10 MATERNOVA INC. 245
15.10.1 COMPANY SNAPSHOT 245
15.10.2 PRODUCT PORTFOLIO 245
15.10.3 RECENT DEVELOPMENT 245
15.11 REVMEDX 246
15.11.1 COMPANY SNAPSHOT 246
15.11.2 PRODUCT PORTFOLIO 246
15.11.3 RECENT DEVELOPMENT 246
15.12 3RD STONE DESIGN 247
15.12.1 COMPANY SNAPSHOT 247
15.12.2 PRODUCT PORTFOLIO 247
15.12.3 RECENT DEVELOPMENTS 247
15.13 STERIMED GROUP 248
15.13.1 COMPANY SNAPSHOT 248
15.13.2 PRODUCT PORTFOLIO 248
15.13.3 RECENT DEVELOPMENTS 248
15.14 UTAH MEDICAL PRODUCTS, INC. 249
15.14.1 COMPANY SNAPSHOT 249
15.14.2 REVENUE ANALYSIS 249
15.14.3 PRODUCT PORTFOLIO 250
15.14.4 RECENT DEVELOPMENTS 250
15.15 SINAPI BIOMEDICAL 251
15.15.1 COMPANY SNAPSHOT 251
15.15.2 PRODUCT PORTFOLIO 251
15.15.3 RECENT DEVELOPMENTS 251
16 QUESTIONNAIRE 252